The Probiotics in Pediatric Asthma Management (PROPAM) Study in the Primary Care Setting: A Randomized, Controlled, Double-Blind Trial with <i>Ligilactobacillus salivarius</i> LS01 (DSM 22775) and <i>Bifidobacterium breve</i> B632 (DSM 24706)

<table class="table-group" id="tab5"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td class="align_left"></td><td class="align_center">Placebo (67 exacerbations)</td><td class="align_center">Active treatment (24 exacerbations)</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td class="align_left">Use of oral corticosteroids</td><td class="align_center">45 (67.2%)</td><td class="align_center">17 (70.8%)</td></tr><tr><td class="align_left">Increased dosage of inhaled corticosteroids</td><td class="align_center">34 (50.7%)</td><td class="align_center">13 (54.2%)</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Treatment during asthma exacerbations in both groups.</div>

Journal of Immunology Research

tab5

Table 5

Table 5: The Probiotics in Pediatric Asthma Management (PROPAM) Study in the Primary Care Setting: A Randomized, Controlled, Double-Blind Trial with <i>Ligilactobacillus salivarius</i> LS01 (DSM 22775) and <i>Bifidobacterium breve</i> B632 (DSM 24706) 

Table 5 | The Probiotics in Pediatric Asthma Management (PROPAM) Study in the Primary Care Setting: A Randomized, Controlled, Double-Blind Trial with Ligilactobacillus salivarius LS01 (DSM 22775) and Bifidobacterium breve B632 (DSM 24706) 